10-K · February 27, 2026
ANI Pharmaceuticals strengthened its Rare Disease footprint in 2025 via the Alimera acquisition (ILUVIEN/YUTIQ) and an expanded ILUVIEN label (March 2025), while growing top-line sales (FY2025 revenue approx. $883.0M)…
Earnings analysis · 10-Q
ANIP earnings analysis
Filed May 8, 2026 · Our reading of the company's report
The latest report
ANI Pharmaceuticals reported a strong performance for Q1 2026 with revenue of $237.5 million, exceeding estimates and reflecting a 20.5% year-over-year increase. Additionally, EPS came in at $1.28, surpassing the…
Read full summary
ANI Pharmaceuticals reported a strong performance for Q1 2026 with revenue of $237.5 million, exceeding estimates and reflecting a 20.5% year-over-year increase. Additionally, EPS came in at $1.28, surpassing the consensus estimate of $1.23, while the company raised its guidance for full-year revenue and EPS outlook, indicating positive growth prospects.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.28
- Segment
- Rare Disease
- Segment
- Brands
- Segment
- Generics
What stood out
-
Strong Revenue Beat
Q1 2026 revenue reached $237.5 million, up 20.5% from $197.1 million in Q1 2025.
-
Improved EPS
Diluted EPS for Q1 2026 was $1.28, exceeding the estimated $1.23.
-
Rare Disease Segment Growth
Rare Disease and Brands revenue increased by $34.2 million to $128.2 million, a 36.3% growth.
-
Cortrophin Gel Sales Surge
Sales of Cortrophin Gel grew 42.1% to $75.1 million compared to $52.9 million in Q1 2025.
-
Increased Cash Flow
Operating cash flow improved to $58.4 million, up from $35.0 million a year earlier.
-
Raised Full-Year Guidance
Full-year revenue guidance increased to $1,080 million - $1,140 million from a prior range of $1,055 million - $1,115 million.
What to watch
-
Litigation Expenses
Potential litigation expenses impacting profitability, as highlighted in the 10-K.
-
Market Competition
Increasing competition in generic and branded products could pressure margins.
-
Supply Chain Risks
Reliance on a limited number of suppliers for raw materials could affect production.
Management's outlook
Increased guidance reflects strong sales performance and market demand.
Earlier filings 4
10-Q · August 6, 2024
ANI reported Q2 net revenues of $138.04M (up $21.49M or ~18.4% YoY from $116.55M) but recorded a Q2 net loss of $(2.287)M (basic/diluted loss per share $(0.14)). Six‑month results improved: operating income for the six…
10-Q · August 9, 2023
ANI reported materially stronger Q2 results versus prior-year Q2 with net revenues of $116,547,000 (up from $73,855,000) and a return to operating profit of $12,402,000 versus an operating loss of $(12,913,000) in Q2…
10-Q · May 8, 2023
ANI Pharma reported strong top-line growth: net revenues of $106,786,000 in Q1 2023, up from $64,477,000 in Q1 2022. The company swung to operating income of $9,895,000 (9.3% operating margin) from an operating loss of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.